Pediatric Bone Quality Across Growth Spurts

Abstract

Pediatric bone quality is a dynamic parameter influenced by rapid growth and hormonal changes during childhood and adolescence. Growth spurts, particularly during puberty, exert a profound impact on bone mineral accrual and microarchitecture, with significant implications for lifelong skeletal health. This review synthesizes recent evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, and management of bone quality in pediatric populations, and discusses emerging therapies and guideline recommendations relevant to clinicians managing pediatric bone health.

Introduction

Pediatric bone quality serves as a cornerstone for achieving optimal peak bone mass a critical determinant of future fracture risk and osteoporosis in adulthood. Growth spurts, notably in the peripubertal period, represent windows of heightened skeletal vulnerability and opportunity. Understanding the biological mechanisms governing bone remodeling during these periods, as well as the clinical implications, is essential for pediatricians, endocrinologists, and orthopedic specialists. This article provides a comprehensive review of pediatric bone quality across growth spurts, integrating recent clinical evidence and guideline-based recommendations.

Epidemiology / Disease Burden

The incidence of pediatric bone fragility disorders, including fractures, has increased over the past two decades, correlating with lifestyle changes and chronic disease prevalence. Peak bone mass is typically achieved by late adolescence, with up to 90% of adult bone mass established by age 18 in females and 20 in males. Epidemiological studies highlight that up to 40% of children sustain at least one fracture before adulthood, with a notable surge during pubertal growth spurts. Disparities in fracture rates are observed based on sex, ethnicity, physical activity, nutritional status, and underlying medical conditions, emphasizing the multifactorial nature of bone health in this population.

Pathophysiology

Bone accrual during growth is regulated by a complex interplay of genetic, hormonal, nutritional, and mechanical factors. The pubertal growth spurt, triggered by increased secretion of growth hormone, insulin-like growth factor-1 (IGF-1), and sex steroids, accelerates both longitudinal and appositional bone growth. However, the rapid increase in bone length often outpaces mineralization, resulting in transiently reduced bone mineral density (BMD) and increased susceptibility to fractures. Remodeling dynamics are further influenced by parathyroid hormone, vitamin D, and local cytokines, all modulating osteoblast and osteoclast activity. Genetic mutations affecting collagen synthesis or bone matrix proteins may also compromise bone quality during these critical periods.

Risk Factors

Multiple risk factors can adversely impact bone quality during growth spurts. These include inadequate calcium and vitamin D intake, sedentary lifestyle, chronic inflammatory or endocrine conditions (such as juvenile idiopathic arthritis, type 1 diabetes, or hypothyroidism), and prolonged use of corticosteroids or anticonvulsants. Genetic disorders, such as osteogenesis imperfecta, and nutritional deficiencies due to eating disorders or malabsorption syndromes, also play significant roles. Sex-based hormonal differences during puberty may temporarily disadvantage female adolescents, particularly those with delayed menarche or menstrual irregularities.

Clinical Features

Clinical manifestations of compromised bone quality in pediatric patients range from asymptomatic low BMD to recurrent low-impact fractures, skeletal pain, and, in severe cases, deformities such as scoliosis or vertebral compression. Subclinical bone fragility may only be revealed through incident fractures or during evaluation for underlying chronic disease. Physical examination findings are often subtle but may include tenderness, deformity, or reduced mobility. Growth charts and pubertal staging are essential tools in clinical assessment.

Diagnosis

Diagnosis of bone quality deficits in children hinges on a combination of clinical assessment, imaging, and laboratory evaluation. Dual-energy X-ray absorptiometry (DXA) remains the gold standard for assessing BMD, with results interpreted according to age- and sex-adjusted Z-scores. Peripheral quantitative computed tomography (pQCT) and high-resolution peripheral QCT (HR-pQCT) provide insights into bone microarchitecture and volumetric density, offering advantages in research settings. Laboratory investigations focus on calcium, phosphate, vitamin D, parathyroid hormone, and markers of bone turnover. Genetic testing is reserved for suspected inherited bone disorders.

Treatment & Management

Management of pediatric bone fragility prioritizes addressing underlying causes and optimizing modifiable risk factors. Nutritional interventions include ensuring adequate intake of calcium and vitamin D, with supplementation as needed. Weight-bearing physical activity is strongly encouraged to stimulate bone formation. Pharmacologic therapy, such as bisphosphonates, is reserved for severe cases, including osteogenesis imperfecta or disease-related osteoporosis, and requires specialist oversight due to potential long-term effects on bone modeling. Treating comorbidities, minimizing glucocorticoid exposure, and managing delayed puberty are integral to comprehensive care.

Recent Advances / Emerging Therapies

Recent advances in pediatric bone research have illuminated the roles of Wnt signaling, sclerostin inhibition, and anabolic agents in bone formation. Monoclonal antibodies targeting sclerostin (e.g., romosozumab) are under investigation for pediatric use. Novel imaging modalities such as HR-pQCT enable more precise assessment of bone microstructure and strength. Personalized medicine approaches, leveraging genetic and biomarker profiling, are emerging to tailor interventions for at-risk children. There is also growing interest in optimizing the timing of interventions to coincide with periods of maximal skeletal responsiveness during growth spurts.

Guideline Recommendations

International and national pediatric bone health guidelines emphasize early identification of at-risk children, routine assessment of dietary intake and physical activity, and the use of DXA scanning in those with recurrent fractures or chronic disease. The International Society for Clinical Densitometry (ISCD) recommends interpreting pediatric DXA results using Z-scores, not T-scores, and considering clinical context. Endocrine Society guidelines advocate for supplementation and management of underlying endocrine or inflammatory conditions. Pharmacologic therapy is reserved for defined indications with documented fragility fractures or persistent low BMD despite lifestyle optimization.

Conclusion

Pediatric bone quality during growth spurts represents a critical determinant of lifelong skeletal health. Clinicians must recognize the heightened vulnerability during rapid growth periods and proactively address modifiable risk factors through targeted nutritional, lifestyle, and medical interventions. Advances in imaging and molecular therapies hold promise for more effective, individualized care. Multidisciplinary approaches guided by current evidence and best practice recommendations are essential to optimize bone health outcomes in the pediatric population.